Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval
China’s oncology-focused biotech hub has raised already millions in venture funding and lured powerful global biopharma partners to address the high rates of cancer in the country. In yet another example, the joint venture between Juno and to WuXi’s AppTec has raised a sizable $100 million in a fresh round of funding.
The Shanghai-based company, christened JW Therapeutics (an initial each from its root companies), was created to marry Juno’s CAR-T development experience and WuXi’s AppTec’s muscular manufacturing capacity. In 2018, it scored $90 million to take its lead experimental B cell malignancy-focused drug, JWCAR029, into the clinic and build a new manufacturing plant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
